Abstract: Modafinil polymorphic forms of modafinil racemate, methods of preparation thereof, pharmaceutical compositions and methods of therapeutic treatment involving modafinil polymorphic forms.

Abstract: A ? crystalline form of the compound of formula (I): characterized by its powder X-ray diffraction data. Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.

Abstract: An ? crystalline form of the compound of formula (I): characterized by its powder X-ray diffraction data. Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.

Abstract: A &ggr; crystalline form of the compound of formula (I): 1

Abstract: The subject of the present invention is the various polymorphic forms I, II, III, IV of benzyl (S,S)-2-(2-acetylsulphanylmethyl-3-benzo[1,3]dioxol-5-ylpropionyl-amino)propionate, hereinafter called Fasidotril, their methods of preparation and novel pharmaceutical compositions containing them.

Abstract: Modafinil polymorphic forms of modafinil racemate, methods of preparation thereof, pharmaceutical compositions and methods of therapeutic treatment involving modafinil polymorphic forms.

Abstract: &bgr; crystalline form of the compound of formula (I): 1

Abstract: The subject of the present invention is the various polymorphic forms I, II, III, IV of benzyl (S,S)-2-(2-acetylsulphanylmethyl-3-benzo[1,3]dioxol-5-ylpropionyl-amino)propionate, hereinafter called Fasidotril, their methods of preparation and novel pharmaceutical compositions containing them.

Abstract: &agr; crystalline form of the compound of formula (I): 1

Abstract: &ggr; crystalline form of the compound of formula (I): 1

Abstract: This invention relates to a method of splitting 1-amino-alkan-2-ol compounds of general formula: in which the group R can represent a wide variety of linear, branched or cyclic alkyl groups, comprising up to about 20 to 25 carbon atoms and preferably 1 to 15 carbon atoms. These groups can possibly have one or more double bonds, one or more hetero-atoms such as oxygen or sulfur so long as these are to be found separated from the asymmetric carbon atom by at least one carbon link and do not destroy the aliphatic nature of the group R. These groups can also be substituted by one or more halogen atoms such as chlorine or lower alkoxy groups such as methoxy or ethoxy groups.

Abstract: A method of optical enantiomer resolution by preferential crystallization involves entering, each time crystallization starts, the two-phase domain containing excess enantiomer and the saturated solution, and cooling according to a well-defined kinetic schedule. A racemic mixture of fine particle size is added to the mother liquors obtained after harvesting the crystals, the mother liquors then being heated to a temperature lower than that of homogenization of the solution so that excess enantiomer is present only in a solid state in equilibrium with the solution. Further cooling produces the other enantiomer and completes the cycle of operations which may then be carried out repetitively.

Abstract: Method of resolution of chiral hydantoins of the general formula I ##STR1## in which: R.sub.1 designates a lower alkyl radical comprising 1 to 5 carbon atoms in linear or branched chain,R.sub.2 designates a phenyl radical, possibly mono-, di-, or tri-substituted by lower alkyl or alkoxy radicals or halogen atoms, whether identical of different, or a heteroaryl radical containing a ring of 5 to 7 members in which the sole hetero atom is nitrogen, oxygen or sulfur, or else an aralkyl radical the alkyl part of which comprises one or two carbon atoms and the aryl ring is a phenyl group possibly mono-, di- or tri-substituted by radicals which are lower alkyl or alkoxy radicals or halogen atoms, whether identical or different. The hydantoin (I) to be resolved is dissolved in an alcohol or an alkaline solution, and an enantiomer of .alpha.